Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy - - BioPharm International

ADVERTISEMENT

Podcast: Flexion's CEO Mike Clayman on Targeting Key Therapeutic Areas as a Business Strategy


blog comments powered by Disqus


Angie Drakulich, Editorial Director of BioPharm International, talks with Mike Clayman, CEO of Flexion Therapeutics. Based in Woburn, MA, the company works to develop therapeutics for musculoskeletal disorders. In this podcast, Clayman discusses why the company chose to focus on a full range of treatments for one particular disease, osteoarthritis, and how the approach has helped the company fill its biopharmaceutical pipeline and market space. Posted Apr. 2012.

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here